Although a full remission due to the excellent synergy of Ibrutinib (9 periods) and Venetoclax (6 periods) there is still a level of approx 10 percent of cll disease in my pb. Ofcourse I hoped to be one of the succesful cohort Dr. William Wierda presented on Asco 2018; more than 70 percent seems to get to this impressive result within a few months. I will have another evaluation after period 12 and 15. So MRD - could be in reach for me too. I had to stop taking Vtclx for a week and reduce the dose for another week due to neutrophelia in period 9. Fingers crossed🤞🏻.
Yvonne
Written by
Yvbb
To view profiles and participate in discussions please or .
Hi Mike, I replied earlier, but it looks like it didn’t go through. The 400 mg is a little bit challenging. I am experiencing nausea and a lot of fatigue. I have decided to change the timing from morning to night, so I am slowly moving up the time when I take both medications until I get to about 9:30 PM for Ibrutinib and then 10:30 pm for venetoclax. I think I’m in the minority, most people tolerate it well.
Yvbb it looks like you are headed that way - to MRD! Great news! Dr. Wierda is also my doctor and I hope I make to MRD as well although I'm not there yet. Just had my 4th BMB but don't know the results of it yet. My fingers are crossed - for both of us! Keep on keeping on.
Thank you so much for the support. I read this somewhere: it is not all about the medicine, it is the luck you can have and the support that can make the difference.❤️
I was one of the first 14 on the trial and wasn't MRD- at your stage either. After the 15 month evaluation though, I reached MRD- "undetectable" as did 11 others (12 from 14). It takes a little while to keep hammering on the toughest of those nasty little CLL cells.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.